|RFx ID :||23479015|
|Tender Name :||Aseptic Compounding for DHBs (chemotherapy, antibiotics and misc. compounding)|
|Reference # :||30275|
|Open Date :||Thursday, 22 October 2020 2:00 PM (Pacific/Auckland UTC+13:00)|
|Close Date :||Monday, 30 November 2020 10:00 AM (Pacific/Auckland UTC+13:00)|
|Department/Business Unit :||Procurement|
|Tender Type :||Request for Proposals (RFP)|
|Tender Coverage :||Syndicated Opportunity [?]|
|Exemption Reason :||None|
|Required Pre-qualifications :||None|
|Alternate Physical Delivery Address :|
|Alternate Physical Fax Number :|
District Health Boards (DHBs) have a requirement for aseptically compounded pharmaceutical products and services (Aseptic Compounding) for a wide range of uses.
Aseptic Compounding refers to the handling and processing of sterile ingredients to create an end product that remains sterile. Such processing is often required when a high degree of dose customisation is required, no commercial alternatives are available or an immediate pharmacological effect is required.
The Aseptic Compounding process requires clean room environments with cabinets/isolators that are consistently monitored for air flow, humidity, pressure changes, temperature and contamination.
While some DHBs have in house compounding units, sterile products may also be sourced from:
• Private suppliers of aseptically compounded products
• Aseptic compounding units of other DHBs
As at the time of writing, the national contract for Aseptic Compounding is set to expire in January 2021. This presents an opportunity for NZ Health Partnerships to promote competitiveness, encouraging new supplier participation and exploring alternative solutions for Aseptic Compounding.